超选择性肝动脉栓塞化疗治疗中晚期肝癌269例疗效观察

Clinical Effects of Ultraselective Transcatheter Arterial Chemoembolization Therapy for Middle and Advanced Stage Liver Cancer in 269 Cases

目的探讨超选择性肝动脉栓塞化疗(TACE)治疗中晚期肝癌的临床疗效。方法对436例中晚期肝癌患者中的269例行TACE治疗,167例行TACT治疗,观察两组的临床疗效。结果 TACT组最长生存时间为18个月,TACE组为42个月。6、12个月生存率分别为69.6%、23.2%(TACT组)和92.2%、68.6%(TACE组),两组间比较差异有统计学意义(P<0.01)。结论 TACE治疗中晚期肝癌患者疗效显著,并能明显延长患者的生存时间。

Objective To investigate the clinical effects of ultraselective transcatheter arterial chemoembolization therapy for middle and advanced stage liver cancer.Methods 269 patients of middle and advanced stage liver cancer received TACE treatment and 167 patients of middle and advanced stage liver cancer received TACT treatment.Results In TACE treatment group,the longest survival time was 42 months,and the survival rates were 92.2%,68.6%at 6 months,12 months.In TACT treatment group,the longest survival time was 18 months,and the survival rates were 69.6%,23.2% at 6 months,12 months,respectively.There was significant difference between the two groups（P0.01）.Conclusion TACE may be effective obviously for advanced liver cancer,and could prolong survival time of liver cancer patients.